SEC Form 4 · accession 0001437749-26-025709
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Brynjelsen
Officer — President & CEO · Director
Period of report
Jul 31, 2026
Accepted (ET)
Aug 4, 2026 · 5:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF1 | — | Jul 31, 2026 | A | 128,985 | A | — | — | Common Stock | 128,985 | 128,985 | D |
Explanation of responses
- F1On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for an indefinite duration.